Protagonist Therapeutics, Inc.
NASDAQ:PTGXBiotechnology
+$1.72 today
- Market cap
- $8.30B
- Beta
- 1.83
- P/E (TTM)
- -64.2
- EPS (TTM)
- -$1.76
Volume 0.43M
Average 0.72M
PTGX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Protagonist Therapeutics, Inc.NASDAQ: PTGX
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q2 FY2026 accounts receivables of $40.25M rose 7380.9% year over year, ahead of the -2409.1% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +238.7% a year.
Context
- Accounts receivables amounted to 358.3% of revenue in FY2025, up 322.6 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +7380.9% holds above the trailing-twelve-month pace of -2409.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 164.88M USD
- Year-over-year change
- +206.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 164.88M | +206.4% |
| FY2024 | 2024-12-31 | (155M) | -1451.6% |
| FY2023 | 2023-12-31 | (9.99M) | -335.5% |
| FY2022 | 2022-12-31 | 4.24M | +563.6% |
| FY2021 | 2021-12-31 | (915K) | — |
Accounts Receivables vs competitors
How PTGX compares with its peers on the latest reported figures
- PTGX's LTM Jun 2026 accounts receivables of $13.42M is the largest of the 7 companies compared; the peer median is $0.
- Its year-over-year change of -2409.1% is the lowest of 4, against a peer median of +89.6%.
- Accounts receivables amounts to 4.8% of revenue for PTGX, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13.42M | -2409.1% | +238.7% | 4.8% | |
| LTM Mar 2026 | $7.86M | +44.2% | — | 3.4% | |
| LTM Mar 2026 | $6.81M | +5438.2% | +253.5% | 81.4% | |
| LTM Sep 2026 | $510K | +89.6% | — | 7.2% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding PTGX) | $0 | +89.6% | +253.5% | 5.3% | |
Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.55M) | (127.39M) | (78.96M) | 275.19M | (130.15M) |
| Depreciation & Amortization | 2.78M | 3.37M | 3.31M | 2.96M | 1.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.4M | 24.2M | 29.29M | 37.55M | 45.97M |
| Change in Working Capital | (3.31M) | (7.77M) | (19.51M) | (122.61M) | 146.21M |
| Accounts Receivables | (915K) | 4.24M | (9.99M) | (155M) | 164.88M |
| Inventory | 915K | (4.24M) | 0 | 0 | 0 |
| Accounts Payables | (1.39M) | 2.05M | (2.87M) | 842K | 3.72M |
| Other Working Capital | (1.92M) | (9.81M) | (6.65M) | 31.55M | (22.39M) |
| Other Non-Cash Items | 1.83M | (549K) | (4.38M) | (8.94M) | (5.64M) |
| Operating Cash Flow | (107.87M) | (108.14M) | (70.24M) | 184.15M | 57.67M |
| Capital Expenditures | (1.1M) | (795K) | (609K) | (1.36M) | (1.59M) |
| Acquisitions (Net) | 14.76M | (91.47M) | 0 | 0 | 0 |
| Purchases of Investments | (286.59M) | (214.87M) | (191.05M) | (621.7M) | (546.59M) |
| Sales of Investments | 271.83M | 307.14M | 152.4M | 323.57M | 498.84M |
| Other Investing Activities | (14.76M) | 91.47M | 0 | 0 | 0 |
| Investing Cash Flow | (15.86M) | 91.47M | (39.26M) | (299.48M) | (49.33M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 123.83M | 14.55M | 132.1M | 26.45M | 23.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.09M | 4.29M | 38.38M | (600K) | (479K) |
| Financing Cash Flow | 129.92M | 18.84M | 170.48M | 25.85M | 22.86M |
| Effect of Forex Changes | (126K) | (90K) | 0 | 0 | (62K) |
| Net Change in Cash | 6.07M | 2.08M | 60.98M | (89.48M) | 31.14M |
| Free Cash Flow | (108.97M) | (108.93M) | (70.85M) | 182.8M | 56.08M |
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
Intrinsic Alpha fair value
Locked
Current Price
$127.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.